Introduction {#sec1}
============

Primary immunodeficiency disorders (PIDs) are a heterogeneous group of genetic disorders characterized by an impaired ability of the immune system to produce a normal immune response. This is due to inherited defects in either cellular or humoral immunity, which results in a spectrum of issues such as recurrent infections, allergies, autoimmunity, and malignancies.[@bib1]^,^[@bib2] In neonates, PIDs often present with severe infections leading to death; whereas in adolescents these infections are less severe albeit recurrent. Diagnosing PIDs is challenging because of the variability in clinical presentation and limited availability of diagnostic tests, particularly in low middle-income countries (LMIC). When diagnostic tests are available, their cost often becomes a limiting factor. Advances in molecular diagnostic techniques and the identification of known gene defects have helped to facilitate the diagnosis of patients with PIDs.[@bib3] The true global prevalence and distribution of PIDs remain unclear. The prevalence statistics available from nationwide registries are mostly derived from limited areas of the world. The data obtained from these registries often underestimate the true prevalence, because not all cases are reported to these registries, and due to ambiguity in what constitutes a PID case, some cases are missed. These issues are compounded in developing countries because of the lack of physician training in identification of these disorders and the limited access to diagnostics in these countries. Recent studies have shown that PIDs are more common than previously thought, and that around 1% of the population may have an underlying PID.[@bib4] The burden of PID varies by region, being highest in the United States of America (USA), followed by Europe, Latin America, Middle East, Asia, and finally Africa.[@bib4] This frequency may be biased by the availability of resources for diagnosis of these disorders.

Most PIDs are autosomal recessive, which makes it safe to assume that the incidence of PIDs is greater in regions having higher rates of consanguinity. However, limited studies have been carried out in such regions and hence the burden and type of PIDs in such areas is relatively unknown. Consanguineous marriages are common in developing Asian countries ranging between 20 and 70% of all marriages, and Pakistan is no different, with about 70% of the marriages being consanguineous.[@bib5], [@bib6], [@bib7] The data on PIDs in Pakistan is currently confined to a few case reports, case series, and editorials; there are no detailed reports on the spectrum of PIDs seen in the country.[@bib8], [@bib9], [@bib10], [@bib11]

Diagnosing and treating PIDs is a challenge in Pakistan. Patients often die before the disorder is recognized by a physician, leading to a delay in diagnosis or death of the child. Families are often referred to tertiary care centers following the death of a sibling or for admission for life-threatening infections. Even in large tertiary care centers with well-equipped laboratories, there are limited diagnostic facilities available for confirming PIDs. Even when these are available, the diagnostic tests are expensive and beyond the reach of most families as the health care system of Pakistan relies on out-of-pocket payments for health expenditures. Once the diagnosis of PID is confirmed, supportive therapies like antibiotic and antifungal prophylaxis, intravenous (I/V), or subcutaneous (S/C) immunoglobulin therapy, depending on the underlying disorder, are offered. Intravenous immunoglobulin (IVIG) is the standard therapy for most humoral deficiencies, but it is expensive and beyond the reach of most patients in low middle income countries (LMICs). S/C immunoglobulins provide ease of administration, but their availability is limited in LMICs. Bone marrow transplant is available in certain settings but has its limitations in countries like Pakistan where no donor registries are available, and the cost of the transplant coupled with the risk of infections in the post-transplant period make this option challenging to pursue. Gene therapy is another promising albeit costly treatment option undergoing experimentation and is now considered an option for the treatment of multiple non-life-threatening disorders (ie, immunological disorders and systemic protein deficiency). This study aims to report the spectrum of PID cases observed at a tertiary care center in Pakistan, with a focus on the molecular diagnosis in this patient population over the last 7 years.

Materials and methods {#sec2}
=====================

The Aga Khan University Hospital (AKUH) is a 700 bed, not-for-profit tertiary care hospital in Karachi, Pakistan. The hospital receives referrals from all over the country. A retrospective chart review of children suspected to have PID was conducted at the AKUH, Pakistan from 2010 to 2016. Data on demographics, clinical features, age at onset of symptoms, age at presentation, history of recurrent infections, skin allergies, family history of consanguinity, sibling death, details related to laboratory workup done for PID (complete blood count, serum immunoglobulin levels, nitrotetrazolium blue test (NBT), dihydrorhodamine(DHR) and flow cytometric analysis) were collected. Molecular tests targeted panel next generation sequencing (NGS) or whole exome sequencing (WES) were performed at Geha laboratory at Boston Children's Hospital, USA. Targeted panel NGS was performed using the PID v2 panel and Ion Torrent™ S5 sequencer (ThermoFisher), with an average coverage of 328x. Variant annotation was performed with VarSeq™ software (Golden Helix). Whole exome sequencing (WES) was performed using a previously described pipeline with an average on-target coverage of 80×.[@bib12] The cost of shipping and molecular testing was covered by a philanthropic grant from the Perkins Fund. Data were analyzed using IBM SPSS Statistics v. 20.0. Mean ± S.D is reported for quantitative variable like age at diagnosis, delay in diagnosis (days), etc. Frequency and percentages are reported for categorical variables such as gender, type of PID, clinical features, history of sibling death, consanguinity in family, mortality, etc.

Results {#sec3}
=======

A total of 43 children visited the hospital with a suspected PID during the study period. Among them, genetic testing was performed in 31/43 (72.1%) children. A confirmed diagnosis was established in 20/43 (46.5%) children. A pathogenic gene variant was identified in 17 (85%) of the 20 confirmed cases ([Table 1](#tbl1){ref-type="table"}). Of the remaining 23 patients, samples for 9 patients were not sent for molecular testing, 7 had no known genetic mutation for PID ([Table 2](#tbl2){ref-type="table"}), no pathogenic genetic variant was identified in 2 patients, 2 died before a final diagnosis could be established, 2 were lost to follow-up, and 1 had normal sequencing results ([Fig. 1](#fig1){ref-type="fig"}). Twelve (60%) of the 20 confirmed children with PID were male. The mean (±S.D) age at the time of diagnosis was 4.2 (±4.1) years. The mean (±S.D) delay in diagnosis was 1333 ± 1420 days. The most common presenting symptom was recurrent diarrhea 11/20 (55%) followed by recurrent pneumonia 8/20 (40%), oral thrush 7/20 (35%), skin rashes and abscesses 6/20 (30%), osteomyelitis 1/20 (5%), and meningitis 1/20 (5%). Chronic granulomatous disease (CGD) was the most common 6/20 (30%) disorder, followed by severe combined immunodeficiency (SCID) 3/20 (15%), leukocyte adhesion deficiency (LAD) 3/20 (15%), agammaglobulinemia/hypogammaglobulinemia 3/20 (15%), and Hermansky-Pudlak Syndrome (HPS) 2/20 (10%). Wiskott-Aldrich Syndrome, Immunodeficiency Centromeric Instability and Facial Anomalies Syndrome (ICF 2), Trichohepatoenteric syndrome (TRES), and C3 deficiency were each diagnosed once {1/20 (4.3%) each} ([Table 1](#tbl1){ref-type="table"}). Of these 20 confirmed cases, almost all 19/20 (95%) had a family history of consanguinity. Sibling death was reported in 5/20 (25%) of these cases. Five out of 20 (25%) children died due to various reasons. A pathogen (*Pneumocystis jiroveci*) was identified in only 1 of the 5 deceased patients. Among the deceased children, 2 developed acute respiratory distress syndrome (ARDS), 2 died of sepsis, and 1 had plastic bronchitis.Table 1Clinical and Laboratory characteristics of patients with a confirmed Primary immunodeficiency disorder.Table 1S.NoAge/SexClinical FeaturesConsanguinitySibling Death (Age/Cause of death)[a](#tbl1fna){ref-type="table-fn"}Special Investigations (Normal range)Mutated GeneFinal DiagnosisAge at onset of symptomAge at diagnosisOutcome**Phagocyte Defects (n** = **9)**111 mo/MRecurrent abscesses and osteomyelitisYesYes (18 mo old brother & 16 days old brother with no apparent cause)**NBT**: Negative\
**DHR:** Positive\
**Immunoglobulins**\
IgG:15.2 (6.5--16)\
IgA: 3.68 (0.4--3.5)\
IgM:1.15 (0.5--3.0)\
IgE: not done\
**Flow cytometry**\
Not done\
**HIV-serology**: not done**Gene**\
NCF1\
**Loss of coverage**\
Exon 2 could not be amplified, suggesting a deletion that includes this exonAR CGDBirth6 yrAlive23.3 yr/MRecurrent abscesses, lymphad enopathyNoYes (9 mo old brother due to pneumonia)**NBT**: Negative\
**DHR**: Not done\
**Immunoglobulins**\
IgG:23.1 (5.7--17.1)\
IgA: 3.58 (0.47--2.5)\
IgM:2.38 (0.64--2.7)\
IgE: not done\
**Flow Cytometry**\
CD3: 5203 (1500--2900)\
CD4: 2328 (1000--2100)\
CD8: 1999 (700--1100)\
CD19: 2407(500--1200)\
CD 56: 556 (300--600)\
**HIV-serology**:Negative**Gene**\
CYBB\
**Zygosity**\
Homozygous\
**Genomic coordinate** c.1222G \> A\
**Amino acid Change** p.Gly408ArgX-linked CGD9 mo8 yr 9 moAlive33 mo/MRecurrent diarrhea, perianal abscess, skin rashYesNo**NBT**: Negative\
**DHR**: Not done\
**Immunoglobulins**\
IgA: 0.2 (0.09--1.07)\
Others: not done\
**Flow Cytometry**\
CD3: 1652(1800--3300)\
CD4: 1224 (900--2300)\
CD8: 237 (700--1500)\
CD19: 839(700--1700)\
CD 56: not done\
**HIV status:** not checked**Gene**\
NCF1\
**Zygosity**\
Homozygous\
**Genomic coordinate** c.294_295insA **Amino acid change**\
p.Gly99fsAR CGD2 mo2 yr 9 moAlive41.3 yr/FRecurrent diarrhea, cow milk protein allergyYesYes (1.5 years old sister due to septic shock & had similar complaints, no workup done for PID)**NBT**: Absent activity\
**DHR**: Not done\
**Immunoglobulins**\
IgG:13.4 (6.5--16.0)\
IgA:2.49 (0.4--3.5)\
IgM:1.14 (0.5--3.0)\
IgE: 1336 (0.4--351.6)\
**Flow cytometry**\
CD3: 5030 (1900--2900)\
CD4: 3617 (1000--1800)\
CD8: 1388 (700--1200)\
CD19: 5073(600--1400)\
CD56:1279 (300--600)\
**HIV status:** not checked**Gene**\
NCF2\
**Zygosity**\
Homozygous\
**Genomic coordinate**\
Chr1:183532647\
**Loss of coverage**:\
1098_1099delTC = p.Gln367fs (Frameshift deletion)AR CGDBirth2 yrAlive53 yr/MRecurrent pneumonias, oral thrush, perianal abscess lymphadenopathyYesNo**NBT**: Normal\
**DHR:** Not done\
**Immunoglobulins**\
IgG: 7.62 (.05--14.0)\
IgA:1.56((0.18--1.7))\
IgM: 1.20(0.63--2.9)\
IgE: \>2000(0.4--351.6)\
**Flow cytometry**\
CD3: 6124(1500--2900)\
CD4: 3355(1000--2100)\
CD8: 2539(700--1100)\
CD19:1830(500--1200)\
CD56:not done\
**HIV serology**: Negative**Gene**\
NCF1\
**Zygosity**\
Homozygous\
**Genomic coordinate**\
Chr7: 74191664\
**Amino acid change** p.Arg42TrpAR CGD2 yr4 yr 5 moAlive6.7 yr/MRecurrent pneumoniaYesNo**NBT**: Not done\
**DHR**: Positive\
I**mmunoglobulins**\
Not done\
**Flow cytometry**\
Not done\
**HIV status**: not checkedNot doneCGD9 mo7 yrAlive7.3.5 mo/FDelayed shedding of umbilical cord, recurrent oral thrush, skin rash,YesNo**Immunoglobulins**\
Not done\
**Flow cytometry**\
Not done\
**HIV status**: not checked**Gene**\
FERMT3\
**Zygosity**\
Homozygous\
**Loss of coverage** (Kindlin-3)c.126_126delC = p.Ile42fs (Frameshift deletion)LAD32 mo1yr 4 moAlive8.7 mo/FDelayed shedding of umbilical cord, recurrent diarrhea, skin rashYesNo**Immunoglobulins**\
IgG:4.02 (6.5--16)\
IgM:1.36 (0.5--3.0)\
IgA: 0.36 (0.4--3.5)\
IgE: 31.0 (1.4--52.3)\
**Flow Cytometry**\
CD3: 3987 (2800--3500)\
CD4: 3122 (1700--2400)\
CD8: 784 (800--1100)\
CD 56: 444 j(300--800)\
CD19: 2168 (1000--1700)\
**HIV status:** not checked**Gene**\
ITGB2\
**Zygosity:** Homozygous\
**Genomic coordinate** (GRCh37/hg19): c.134G \> A\
**Amino acid change** p.Trp45Ter (Nonsense)LAD112 days5 moAlive9.4 mo/MDelayed shedding of umbilical cord and umbilical abscessYesNo[c](#tbl1fnc){ref-type="table-fn"}**Flow cytometry for LAD markers:**\
CD11C deficiencyNot doneLAD2Birth3 moAlive**Combined/Cellular defects (n** = **7)**10.4 mo/MRecurrent diarrhea, skin rashYesNo**Immunoglobulins**\
IgG: \<0.7 (6.5--16.0)\
IgA: \<0.15 (0.4--3.5)\
IgM: 0.0 (0.5--3.0)\
IgE: 440 (1.4--52.3)\
**Flow Cytometry**\
CD3: 150 (1800--3300)\
CD4: 150 (900--2300)\
CD8: 1 (700--1500)\
CD56:108 (300--800)\
CD19: 0 (700--1700)\
**HIV status:** not checked**Gene**\
RAG2\
**Zygosity**\
Homozygous\
**Genomic coordinate** c.1247G \> T\
**Amino acid change** p.Trp416LeuSCID Omenn syndrome1.5 mo5 moAlive11.5 mo/FRecurrent pneumonia, diarrhea, otitis media, skin rashYesNo**Immunoglobulins**\
IgG:0.66 (1.9--7.9)\
IgA: \<0.15 (0.01--0.59)\
IgM: not done\
IgE: 18 (1.4--52.3)\
**Flow Cytometry**\
CD3: 428 (2800--3500)\
CD4: 283 (1700--2400)\
CD8: 122 (800--1100)\
CD56: not done\
CD19: 25(1000--1700)\
**HIV serology**: Negative**Gene**\
RAG1\
**Zygosity**\
Homozygous\
**Genomic coordinate**\
Chr 11: 36597688_A \> T = c. 2834 A \> T\
**Amino acid change** p.H945L\
**SIFT** (0.01);\
**Polyphen** (0.969).SCID3 mo6moDied due to [b](#tbl1fnb){ref-type="table-fn"}ARDS and [b](#tbl1fnb){ref-type="table-fn"}PCP pneumonia\
(1 month *before establishing diagnosis*)12.1 yr/FRecurrent diarrhea, oral thrushYesNo**Immunoglobulins**\
Ig G: 0.83 (not available)\
IgA: 0.17 (not available)\
IgM: 0.23 (not available)\
IgE: not done\
**Flow cytometry**\
CD3: 32 (not available)\
CD4: 6 (not available)\
CD8: 23 (not available)\
CD19: 397 (not available)\
**HIV serology**: Negative**Gene**\
JAK3\
**Amino acid change** p.P402L.\
**SIFT** (0).\
**Polyphen** (0.85)SCID8 mo1 yr 2 moDied due to [b](#tbl1fnb){ref-type="table-fn"}ARDS\
(2 months *before establishing diagnosis*)132.5 yr/MOral thrush, skin rash, Food allergy, anemia, thrombocytopeniaYesNo**Immunoglobulins**\
Ig G:19.4 (not available)\
Ig A: 2.99(not available)\
Ig M: 0.76(not available)\
Ig E: \>5000(not available)\
**Flow Cytometry**\
CD3: 1126(not available)\
CD4: 285(not available)\
CD8: 675(not available)\
CD19: 75(not available)\
CD56: 299(not available)\
**HIV status**: not checked**Gene**\
WAS\
**Zygosity**\
Hemizygous\
**Genomic coordinate**\
ChrX: 48543941 (Deletion of C)Arg94fs (Frameshift deletion)WAS9 mo3 yr 1 moDied due to sepsis\
(5 months *before establishing diagnosis*)14.9 mo/FRecurrent diarrhea, pneumonia, oral and perianal candidiasisYesNo**Immunoglobulins**\
IgG: 4.6 (6.5--16)\
IgA: \<0.33 (0.4--3.5)\
IgM: 0.21 (0.5--3.0)\
Ig E: 1.23 (1.4--52.3)\
**Flow cytometry**\
CD3: 4286 (1900--2900)\
CD4: 2942 (1000--1800)\
CD8: 824 (700--1200)\
CD56: 331 (300--600)\
CD19: 944 (600--1400)\
**HIV status:** not checked**Gene**\
ZBTB24\
**Zygosity**\
Homozygous\
**Genomic coordinate**\
Chr6:109802832 c.396_397delTA = p.His132fs (Frameshift deletion)ICF 24 mo1 yr 10 moDied due to Plastic bronchitis.\
(2.5 months *after diagnosis*)156 yr/MRecurrent diarrhea, pneumonia, occulo-cutaneous albinism, blond hairs, easy bruisibility, oral thurshYesNo**Immunoglobulins**\
Ig G: 9.7 (6.5--16)\
Ig A: 4.0 (0.4--3.5)\
IgM: 0.28 (0.5--3.0)\
IgE: 28 (0.5--393)\
**Flow cytometry**\
Not done\
**HIV status:** not checkedNo pathogenic variant found *(Diagnosed on the basis of clinical findings and family history of similar illness in his first cousin)*Hermansky-Pudlack syndromeBirth7 yrAlive16.16 y/FRecurrent diarrhea, pneumonia, occulo-cutaneous albinism, blond hairs, easy bruisibility, oral thrush, epistaxis, otitis mediaYesYes (2.5 years old brother due to pneumonia & had similar features and complaints)**Immunoglobulins**\
Ig G:17.8 (6.5--16)\
Ig A: 4.48 (0.4--3.5)\
IgM: 0.45 (0.5--3.0)\
IgE: 12.0 (1.9--170)\
**Flow cytometry**\
CD3:1330 (720--2320)\
CD4: 592 (430--1010)\
CD8: 687 (170--1050)\
CD19:175 (100--430)\
CD56: 48 (100--430)\
**HIV serology**:NegativeNot done *(Diagnosed on the basis of clinical findings and family history of similar illness in her first cousin)*Hermansky-Pudlack syndrome1 yr17 yrAlive**Humoral/Antibody defects (n** = **3)**17.3 yr/MRecurrent diarrhea\
Recurrent abscessesYesNo**Immunoglobulins**\
IgG: \<0.7 (5.7--17.1)\
IgM: \<0.08 (0.64--2.7)\
IgA: \<0.15 (0.47--2.5)\
IgE: 51 (0.4--351.6)\
**Flow cytometry**\
CD3: 1444 (1500--2900)\
CD4: 389 (1000--2100)\
CD8: 1064 (700--1100)\
CD19: 2 (500--1200)\
CD56: 165 (300--600)\
**HIV serology**: Negative**Gene**\
BTK\
**Loss of coverage** frameshift deletion resulting in exon18 = c.1883delC = p.T628fsX-linked Agammaglobulinemia2yr4yr 9 moDied due to sepsis\
(4 months *before establishing diagnosis*)18.8 yr/FRecurrent diarrhea and pneumoniaYesNo**Immunoglobulins**\
IgG:1.11(7.3--15.1)\
IgM: 0.14(0.55--2.1)\
IgA: \<0.15 (0.7--3.25)\
IgE: \<0.1 (0.5--393)\
**Flow cytometry**\
CD3: 3472(1300--2200)\
CD4: 1513 (600--1100)\
CD8: 1787(500--1000)\
CD19: 49(300--500)\
CD56:176(300--500)\
**HIV status:** not checked**Gene**\
TCF3\
**Zygosity**\
Homozygous\
**Loss of coverage**\
Total loss of coverage of exons 5--11.Agammaglobulinemia1 yr8 yr 7 moAlive19.1.9 yr/MRecurrent pneumoniaYesYes (5 years old brother due to measles)**Immunoglobulins:**\
IgG: 9.64 (6.5--16.0)\
IgM: 0.6 (0.5--3.0)\
IgA: 0.69 (0.4--3.5)\
IgE: 3.37 (0.4--351.6)\
**Flow cytometry:**\
CD3:1653 (1500--2900)\
CD4:1242 (1000--2100)\
CD8: 427 (700--1100)\
CD19: 12 (500--1200)\
CD56: 132 (300--600)\
**HIV status:** not checked**Gene**\
TTC37\
**Zygosity** Homozygous **Genomic coordinates** (GRCh37/hg19): c.1864A \> C\
**Amino acid change** p.Thr622Pro Polyphen: 0.89\
**SIFT**: 0.41Trichohepatoenteric syndrome (THES)Birth1 yr 10 moAlive**Complement Deficiency (n** = **1)**20.4.5 yr/MRecurrent meningitisYesNo**Complement Level**\
C3: 0.05 g/L(0.8--1.5)**Gene**\
C3\
**Zygosity** Homozygous **Genomic coordinates** (GRCh37/hg19): Chr19: 6711208 C \> A (5′ Splicesite, Exon 12)C3 deficiency1 yr5 yrAlive[^1][^2][^3]Table 2Clinical and laboratory characteristics of suspected primary immunodeficiency patients with No known gene mutation for PID.Table 2S.NoAge/SexClinical Features[a](#tbl2fna){ref-type="table-fn"}Special Investigations (Normal range)Suspected diagnosisGene Sequence ResultAge at onset of symptomAge at diagnosisOutcome110 mo/MRecurrent diarrhea**Immunoglobulins**\
IgG:\<0.7 (1.9--7.9)\
IgA:\<0.15 (0.01--0.59)\
IgM:\<0.08 (0.09--2.1)\
IgE:1.0 (1.4--52.3)\
**Flow cytometry**\
CD3:166(1800--3300)\
CD4:132(900--2300)\
CD8: 27 (700--1500)\
CD19: 22(700--1700)\
CD56: 530(300--800)\
**HIV serology:** negativeT^−^B^+^NK^−^SCIDNo Known candidate gene for PID identifiedBirth10 mo.Died due to sepsis22.5 yr/MWork up was done because of family history of SCID.**Immunoglobulins**\
Not done\
**Flow cytometry**\
CD3:503(1500--2900)\
CD4: 451(1000--2100)\
CD8: 68(700--1100)\
CD19:12(500--1200)\
CD56: not done\
**HIV status**: not checkedT^−^B^-^NK^-^ SCIDNo Known candidate gene for PID identified10th day of life1 yr 8 mo.Died due to sepsis36 mo/MFever, leg gangrene, seizures**Immunoglobulins**\
IgG:10.7(6.5--16)\
IgA: 0.31(0.4--3.5)\
IgM:0.2(0.5--3)\
IgE:12.4(1.4--52.3)\
**Flow Cytometry**\
CD3:1140(1800--3300)\
CD4:735(900--2300)\
CD8: 449(700--1500)\
CD56: 49 (300--800)\
CD19: 273(700--1700)\
**HIV serology:** negativeSCIDNo Known candidate gene for PID identified1.5 mo.4 mo.Alive\
No recurrence of infections in follow up. Less likely to be a PID413 yr/MRecurrent diarrhea and joint swelling**Immunoglobulins**\
IgG: 1.11(5.7--17.1)\
IgA: 0.41(0.47--2.5)\
IgM: 0.05(0.64--2.7)\
IgE: 2.85(1.9--170)\
**Flow Cytometry**\
CD3:1718(1100--2200)\
CD4: 651(600--1600)\
CD8: 850(500--1200)\
CD19: 454(200--600)\
CD56: 83(300--600)\
**HIV status:**not checkedNoNo Known candidate gene for PID identified6 yr.13 yr.Alive58 mo/FFever and seizures**Immunoglobulins**\
IgG:13.54(6.5--16)\
IgA: 0.19 (0.4--3.5)\
IgM: 2.8(0.5--3)\
IgE: not done\
**Flow Cytometry**\
CD3:1624(2800--3500)\
CD4: 592(1700--2400)\
CD8: 831(800--1100).\
CD19: 425(1000--1700)\
CD56: 913(300--800)\
**HIV status:** not checkedNoNo Known candidate gene for PID identified4.5 mo.6 mo.Alive611 mo/MRecurrent diarrhea and pneumonia**Immunoglobulins**\
IgG:4.96((6.5--16))\
IgM:0.09(0.5--3)\
IgA: 0.16(0.4--3.5)\
IgE:1.0(1.4--52.3)\
**Flow Cytometry**\
CD3: 244(1800--3300)\
CD4: 105(900--2300)\
CD8: 146(700--1500)\
CD19:1.0(700--1700)\
CD56: 89(300--800)\
**HIV status**: NegativeSCIDNo Known candidate gene for PID identified4 mo.11 mo.Alive\
No recurrence of infections in follow up. Less likely to be a PID75.5 mo/MRecurrent pneumonia, skin rash and hyperglycemia**Immunoglobulins**\
IgG:0.26(6.5--16)\
IgA: 0.09(0.4--3.5)\
IgM:0.12(0.5--3)\
IgE:5.96 (1.4--52.3)\
**Flow cytometry**\
CD3: 2244(1800--3300)\
CD4: 879 (900--2300)\
CD8: 1167(700--1500)\
CD56:196 (300--800)\
CD19: 21 (700--1700)\
**HIV status**: not checkedEarly onset diabetes and Agammaglobulinemia STAT3 GOF?\
LRBA?No Known candidate gene for PID identified2 mo.5 mo.Alive\
Recurrent otitis media, eczematous skin rash and failure to thrive[^4]Fig. 1Study flow showing distribution of study subjectsFig. 1

Discussion {#sec4}
==========

In this case series, 85% of the children were able to get a molecular diagnosis through the support of Boston Children's Hospital. CGD was the commonest disorder observed. This is consistent with data reported from other Asian countries in which phagocytic defects were the most common type of PIDs ranging from 29% to 60%.[@bib13], [@bib14], [@bib15] Almost all cases in this study had a family history of consanguinity. Death of siblings was seen in 25% of the cases. Out of the children who died during the study period, 80% of them were diagnosed after they had died.

Due to a lack of facilities, diagnosing PIDs continues to be a challenge in developing countries. Partnering with international organizations is crucial in aiding and establishing the diagnosis of suspected PIDs in these countries.[@bib9]

Patients with PIDs are often diagnosed based on a clinical history of recurrent infections due to atypical or less virulent pathogens.[@bib16] However, they can also present with non-infectious manifestations, such as autoimmune disease, or albinism.[@bib17] Verma et al published a case series of 27 PID cases in whom recurrent pneumonia and recurrent diarrhea were the most common presentations. In our case series, recurrent diarrhea was the most common clinical presentation followed by recurrent pneumonia, oral thrush, skin rash, and abscesses.[@bib18]

Live vaccines (eg, BCG, OPV) should not be administered to children with PIDs due to the risk of developing mycobacterial disease with the bacillus Calmette−Guérin (BCG) vaccine or Vaccine Derived Poliovirus (VDP) with the oral polio virus vaccine (OPV).[@bib19] Shahmohammadi S et al reviewed 17 cases of disseminated BCG infection in Iran from 2005 to 2010 and observed that 10 (59%) out of the 17 cases had impaired immunity due to an incompetent immune system.[@bib20] In Pakistan, these vaccines (BCG and OPV) are a part of the national immunization programme; hence, they are administered routinely, much earlier before a diagnosis of immunodeficiency can be suspected or established in children. In our case series, almost all cases were vaccinated with the BCG and OPV at birth; so far, none of them have developed any sign of disease due to the vaccination (VDP or Tuberculosis). Although this report is based on a limited number of cases, it does raise the need for a newborn screening program in the long term, so that children suspected of having a PID do not receive a live vaccine at birth.

Early recognition and prompt diagnosis of PIDs help in preventing significant disease related morbidity and mortality. A clinical history and physical examination together with supportive laboratory investigations can provide clues about an underlying PID. Nevertheless, molecular testing plays an essential role in not only confirming the diagnosis but also in identifying the exact nature of the defect. It also assists in patient care as it allows for prognostic counseling.[@bib21]

Varying degree of support for diagnosing PIDs is available from different institutions and philanthropic foundations such as the (International Union of Immunological Sciences (IUIS), European Society for Immunodeficiencies (ESID), Immune Deficiency Foundation (IDF), and Jeffrey Modell Foundation JMF). In most LMICs, diagnostic and therapeutic services are sparse and/or inaccessible. Armed Forces Institute of Pathology (AFIP) in Rawalpindi, Pakistan is a center where limited immune diagnostics are available but molecular techniques are still lacking. Furthermore, this is the only center where some form of diagnostics is available for PIDs. For a country with a population of 200 million and a birth rate of 29.8 births per 1,000 people, a single facility is not enough to meet the demands.

To our knowledge, this is the first report of PID cases from Pakistan confirmed with molecular diagnosis. The cases reported here only reflect cases referred to a large tertiary care center and represent only the tip of the iceberg.

As a next step, we plan to set up a national registry to bring together individual efforts so that medical care for affected individuals can be improved. Having a national registry will facilitate exchange of experience in the diagnosis and management of PIDs with international registries and will help push policies for support of children with an identified PID. We plan to work towards achieving philanthropic support for IVIG/SCIG or bone marrow transplant (BMT) for the treatment of diagnosed patients. Hopefully, these collective efforts will help with early identification of PIDs, aid in tracking and establishing epidemiological data of PIDs in Pakistan, and help decrease the mortality of patients in developing countries around the world.

Conclusion {#sec5}
==========

PIDs are not uncommon in Pakistan; their diagnosis may be missed or delayed due to the overlapping of clinical features of PIDs with other diseases and a lack of diagnostic facilities. There is a need to increase testing capacity for early recognition, diagnosis and management of PIDs to decrease morbidity and mortality. There is also a need to establish a national registry for estimating the true burden of PIDs in the country to aid in policy recommendations.
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[^1]: CD count unit: cells/mm^3^,Immunoglobulin unit: G/L, IgE unit: IU/ml, NBT: Nitrotetrazolium blue test, DHR: Dihydrorhodamine.

[^2]: ARDS: Acute Respiratory Distress Syndrome, PCP: Pneumocystis carini

[^3]: Sample sent to Armed Forces of Institute of Pathology (AFIP), Rawalpindi to check the CD markers for Leukocyte Adhesion Defect (LAD) on flow cytometry

[^4]: CD count unit: cells/mm^3^,Immunoglobulin unit: G/L, IgE unit: IU/ml
